雪莲治疗类风湿性关节炎疗效系统评价

目的系统评价雪莲治疗类风湿性关节炎的临床疗效。方法计算机检索MEDLINE（1996年至2005年11月）、EMBASE（1984年至2005年11月）、Cochrane临床对照试验资料库（2005年第4期）、中国Cochrane中心临床对照实验资料数据库、中国生物医学文献数据库（1978年至2005年11月）,手工检索纳入试验的所有中文及外文文献及相关文献,并逐个进行方法学质量评价,采用RevMan4.2.7软件进行Meta分析。结果共纳入2个半随机对照试验（198例患者）,结果显示,①治愈率：1个研究报道了与湿热麻痹剂比较,治疗前后差异无统计学意义[RR1.81,95%CI（0.40,8.81）];②总有效率：2个研究,与湿热麻痹剂或吲哚美辛比较,治疗前后差异无统计学意义[RR1.21,95%CI（1.00,1.46）;RR 1.23,95%CI（1.02,1.48）]。结论现有的有限证据表明,无法得出其能改善类风湿性关节炎的治愈率、总有效率或病死率等的结论;需要更多设计良好的随机、双盲、安慰剂对照试验加以证实。

A Systematic review clinical effecacy about xuelian treatment for rheumatoid arthritis

Objective To assess the clinical efficacy of Cordyceps sinensis for treating chronic renal diseases. Methods Randomized or Quasi-randomized controlled trials （RCTs or Quasi-RCTs）were identified from MEDLINE （ 1996-2005.11 ）, EMBASE （ 1984-2005. 11 ）, Cochrane Controlled Trials Register （ Issue 4, 2005 ）, Chinese Cochrane Centre Database（ Issue 4,2005 ）, CBMdisc （ 1978-2005. 11 ）. We handsearched related published and unpublished data and their references. All Xuelian treating for rheumatoid arthritis were included. Data were extracted and evaluated by two reviewers independently with designed extraction form. RevMan4.2.7 software was used for data analysis. Results 2 Quasi-RCTs involving 198 patients included. All the results of meta-analysis were listed as the following： ①Cure rate：compared with Shiremabiji, one study showed that Xuelian had no statistical difference with RR1.81 and 95% CI 0.40 to 8.81 ; ②Total effective rate： compared with Shiremabiji or Indometacin, two studies showed that Xuelian had no statistical difference with RR1.21,95% CI 1.00 to 1.46 versus with RR1.23,95% CI 1.02 to 1.48. Conclusion We can＇ t draw a conclusion that Xuelian may increase the cure rate and total effective rate of rheumatoid arthritis. Much higher quality trials are required.